- Home
- EAF vs ALT Comparison
EAF vs ALT Comparison
Compare EAF & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAF | ALT |
|---|---|---|
| Founded | 1886 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.4M | 421.5M |
| IPO Year | 2018 | 2005 |
Fundamental Metrics
Financial Performance| Metric | EAF | ALT |
|---|---|---|
| Price | $7.73 | $3.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $11.75 | ★ $17.67 |
| AVG Volume (30 Days) | 215.8K | ★ 2.6M |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $504,134,000.00 | $41,000.00 |
| Revenue This Year | $4.25 | N/A |
| Revenue Next Year | $12.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $0.55 | $2.87 |
| 52 Week High | $20.32 | $7.73 |
Technical Indicators
Market Signals| Indicator | EAF | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 59.18 | 40.69 |
| Support Level | $7.65 | $2.89 |
| Resistance Level | $7.73 | $4.25 |
| Average True Range (ATR) | 0.64 | 0.17 |
| MACD | 0.28 | 0.05 |
| Stochastic Oscillator | 87.21 | 54.48 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.